Condition
Kjer Optic Atrophy
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Terminated1
Active Not Recruiting1
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06970106Phase 1Recruiting
Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle)
NCT06461286Phase 1Active Not Recruiting
SAD of IVT PYC-001 in OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (Sundew)
NCT06140329Terminated
Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation
Showing all 3 trials